Prevention and treatment of osteoporosis in primary biliary cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 6, 1999, Pages 617-621

  Vleggaar, Frank P ^b   Van Buuren, Henk R ^a   Wolfhagen, Frank H J ^b   Schalm, Solko W ^b   Pols, Huib A P ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Bisphosphonates; Calcium; Corticosteroids; Osteoporosis; Primary biliary cirrhosis; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; FLUORIDE SODIUM; VITAMIN D;

CALCIUM BLOOD LEVEL; CALCIUM DEFICIENCY; CALCIUM INTAKE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY INTAKE; EPIGASTRIC PAIN; HUMAN; NAUSEA; OSTEOPOROSIS; PATIENT MONITORING; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

EID: 0032772688     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199906000-00006     Document Type: Review

References (50)

1. 1• Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990; 31:82-87. Study of prevalence of fractures in patients with chronic liver disease.
2. 2 Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12:273-280.
3. 3 McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AG, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology 1991; 14:613-619.
4. 4 Arnold JC, Hauser D, Ziegler R, Kommerell B, Otto G, Theilmann L, Wuster C. Bone disease after liver transplantation. Transplant Proc 1992; 24:2709-2710.
5. 5•• Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108:276-283. Excellent review on pathogenesis of osteopenia in PBC and primary sclerosing cholangitis (PSC).
6. 6•• Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14:296-300. Comparison of rates of vertebral bone loss for women with and without PBC.
7. 7 Mitchison HC, Malcolm AJ, Bassendine MF, James OF. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988; 94:463-470.
8. 8 Stellon AJ, Davies A, Compston J, Williams R. Osteoporosis in chronic cholestatic liver disease. Q J Med 1985; 57:783-790.
9. 9 Guanabens N, Pares A, Marinoso L, Brancos MA, Piera C, Serrano S, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:1356-1362.
10. 10 Porayko MK, Wiesner RH, Hay JE, Krom RA, Dickson ER, Beaver S, Schwerman L. Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991; 23:1462-1465.
11. 11• Crippin JS, Jorgensen RA, Dickson ER, Lindor KD, Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89:47-50. Retrospective analysis suggesting that oestrogens have a positive effect on bone mass and are safe.
12. 12 Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21:389-392.
13. 13• Van Berkum FN, Beukers R, Birkenhager JC, Kooij PP, Schalm SW, Pols HA. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. Gastroenterology 1990; 99:1134-1139. Higher prevalence of osteoporosis in stage III and IV PBC compared with stage I and II; modest effect of corticosteroid treatment on bone mineral density.
14. 14 Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103:855-860.
15. 15 Almdal T, Schaadt O, Vesterdad Jorgensen J, Lindgreen P, Ranek L. Vitamin D, parathyroid hormone, and bone mineral content of lumbar spine and femur in primary biliary cirrhosis. J Intern Med 1989; 225:207-213.
16. 16 Lindor KD. Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis. Semin Liver Dis 1993; 13:367-373.
17. 17 Parės A. Management of primary biliary cirrhosis: osteoporosis. In: Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment. Lindor KD, Heathcote EJ, Poupon R (editors). Chicago: Kluwer Academic Publishers; 1997. pp. 92-101.
18. 18 Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327:1637-1642.
19. 19 Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-676.
20. 20 Ajdukiewicz AB, Agnew JE, Byers PD, Wills MR, Sherlock S. The relief of bone pain in primary biliary cirrhosis with calcium infusions. Gut 1974; 15:788-793.
21. 21 Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982; 36:426-430.
22. 22 Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20:633-637.
23. 23 Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83:97-102.
24. 24 Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322:802-809.
25. 25 Lundy MW, Stauffer M, Wergedal JE, Baylink DJ, Featherstone JD, Hodgson SF, Riggs BL. Histomorphometric analysis of iliac crest bone biopsies in ptacebo-treated versus fluoride-treated subjects. Osteoporosis Int 1995; 5:115-129.
26. 26 Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991; 1:155-161.
27. 27 Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123:401-408.
28. 28• Guanabens N, Pares A, del Rio L, Roca M, Gomez R, Munoz J, Rodes J. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992; 15:345-349. Placebo-controlled trial showing positive effect of fluoride on bone loss.
29. 29 Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322:1265-1271.
30. 30 Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323:73-79.
31. 31 Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95:557-567.
32. 32 Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-1541.
33. 33• Guanabens N, Pares A, Monegal A, Peris P, Pons F, Alvarez L, et al. Etidronate versus ftuoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113:219-224. Randomized controlled trial comparing fluoride with etidronate treatment; etidronate was more effective.
34. 34 Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A, Chiaramonte M, A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997; 24:239-244.
35. 35 Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10:420-429.
36. 36• Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992; 15:336-344. Study showing that bone loss during corticosteroid treatment in PBC is modest and occurs mainly during the initial phase of therapy.
37. 37 Wolfhagen FH, van Buuren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth J Med 1994; 44:84-90.
38. 38 Wolfhagen FHJ, van Hoogstraten HJF, van Buuren HR, van Berge Henegouwen GP, ten Kate FJW, Hop WCJ, et al. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 1998; 29:736-742.
39. 39 Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996; 25:49-57.
40. 40 Sherlock S, Dooley J. Primary biliary cirrhosis. In: Diseases of the Liver and Biliary System, 9th edn, London: Blackwell Scientific Publications; 1994. pp. 237-24B.
41. 41 Reid IR, Grey AB. Corticosteroid osteoporosis, Baillieres Clin Rheumatol 1993; 7:573-587.
42. 42 LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Sone Miner 1990; 8:39-51.
43. 43 Clements D, Compston JE, Rhodes J, Evans WD, Smith PM. Low-dose corticosteroids in chronic active hepatitis do not adversely affect spinal bone. Eur J Gastroenterol Hepatol 1993; 5:543-547.
44. 44 Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 1986; 45:950-953.
45. 45• Wolfhagen FHJ, van Buuren HR, den Ouden JW, Hop WCJ, van Leeuwen JPTM, Schalm SW, Pols HAP. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. J Hepatol 1997; 26:325-330. Double-blind placebo controlled trial suggesting that etidronate prevents corticosteroid-induced bone loss.
46. 46 Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33:348-350.
47. 47 Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:382-387.
48. 48 Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339:292-299.
49. 49 Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyporbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95:2581-2586.
50. 50 Binkley NC, Suttie JW. Vitamin K nutrition and osteoporosis. J Nutr 1995; 125:1812-1821.